Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Casma Therapeutics

- PMLiVE

Moderna reports positive phase 3 data for its RSV vaccine for older adults

In the US, RSV causes around 60,000 to 120,000 hospitalisations and 6,000 to 10,000 deaths in older adults each year

- PMLiVE

Webcast: The virtual patient: How to use AI-powered conjoint to understand complex treatment decisions

Watch to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes.

Research Partnership

- PMLiVE

Moderna to acquire OriCiro Genomics for $85m

The deal includes the Japanese DNA supplier’s synthetic biology and enzyme technologies

- PMLiVE

CHMP recommends use of Moderna’s Omicron BA.1 booster in children in the EU

The company is also evaluating the use of the vaccine in children aged from six months

- PMLiVE

Merck and Moderna’s personalised cancer vaccine shows promise in high-risk melanoma patients

The vaccine in combination with Keytruda reduced the risk of recurrence or death by 44%

Can Artificial Intelligence Solve the Healthcare Crisis?

Healthcare systems around the world are already struggling to meet the demands of an ageing population, the rising incidence of chronic diseases, escalating healthcare costs and a deficit of healthcare...

Page & Page and Partners

- PMLiVE

FDA approves updated COVID-19 boosters for children aged from six months

The Moderna and Pfizer/BioNTech boosters both target the BA.4/BA.5 omicron subvariants

- PMLiVE

DIGITAL HEALTH IN PRACTICE AND OVERCOMING DIGITAL FATIGUE

During this year’s Reuters event, Pharma 2022, WebMD CMO, Dr John Whyte discussed the ways in which digital health is growing, and the importance of educating clinicians in the right...

Medscape Education Global

- PMLiVE

Merck’s Keytruda meets primary endpoint in phase 3 gastric cancer trial

Gastric cancer is the fourth leading cause of cancer death worldwide

- PMLiVE

Merck to acquire Imago BioSciences in deal worth $1.35bn

The agreement includes lead candidate, bomedemstat, for myeloproliferative neoplasms

- PMLiVE

Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine

Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links